Evidence map›Paper›PMID 40381513›Full record

ArticleVaccine2025

Antigenic and EM characterization of the Chiron experimental hepatitis C virus vaccine.

Shr-Hau Hung, Jonathan L Torres, Fang Chen, Erick Giang, Andrew B Ward, Mansun Law

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shr-Hau HungDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Jonathan L TorresDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Fang ChenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Erick GiangDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Mansun LawDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. Electronic address: mlaw@scripps.edu.

Funding

Novel HCV vaccine antigens and nanoparticlesP01AI168251 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Mansun Law · 2022 to 2026
$12.6M
Understanding human antibody responses to chronic viral hepatitis CR01AI168917 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Mansun Law · 2022 to 2026
$3.1M
NIAID NIH HHS P01 AI168251NIAID NIH HHS R01 AI168917
6 · The paper itself

Abstract

The Chiron experimental HCV vaccine, the only envelope-based HCV vaccine candidate to date, was immunogenic and safe in a phase 1 trial, though its efficacy remains untested. This study examined the antigenic properties of the vaccine antigens by immunoassays and EM, revealing inconsistent presentation of AR1/5 epitopes. The vaccine elicited mainly strain-specific neutralizing antibodies in humans and non-human primates, highlighting the need for rational antigen design to improve vaccine breadth.

Indexed as

HepacivirusHepatitis CViral Hepatitis VaccinesAnimalsAntibodies, NeutralizingEpitopesHepatitis C AntibodiesHumansAntibodies, NeutralizingEpitopesHepatitis C AntibodiesViral Hepatitis VaccinesAntigenicityChiron HCV E1E2Electron microscopyHCV vaccine

Identifiers

PMID40381513
PMCPMC12539379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.